Table 5.
Results of Studies Comparing SCIG With IVIG: Systemic and Local Adverse Event
| Adverse Reaction | During SCIG | During IVIG |
|---|---|---|
| Systemic Reactions | ||
| Severe or anaphylactic reaction | Vagal reaction in 1 patient7 | Anaphylactic reaction occurred in 1 patient20 |
| Fever | 4.7 to 13%7,20,23 | 34%20 |
| Headache | 3 to 8%14,20 | 13.7 to 54%8,21 |
| Dizziness | 2%7,8 | No study reported on this item. |
| Allergic reaction/diffuse skin reaction | 3%7 | 15% to 16%20,21 |
| Nausea/vomiting | 2% to 17%14,23 | 9%20 |
| Diarrhea | 4.7%23 | No study reported on this item. |
| Malaise | 2%7 | No study reported on this item. |
| Infusion Site Reactions | ||
| Reactions such as pain, rash, induration, redness, swelling, soreness, itching, bruising | 2% to 100%8,14,17,20,21,23,26,27 one-fourth of infusions7 | Not applicable |
Abbreviations: NA, not available; IVIG, hospital-based intravenous immunoglobulin; SCIG, home-based subcutaneous immunoglobulin.